Treatment A: BGF MDI HFA
Sponsors
AstraZeneca
Conditions
Chronic Obstructive Pulmonary DiseaseHealthy
Phase 1
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
CompletedNCT06297668
Start: 2024-04-29End: 2024-06-11Updated: 2025-08-13
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
WithdrawnNCT06340581
Start: 2024-10-17End: 2025-02-27Updated: 2025-08-15